Anna Z Mykytyn
Overview
Explore the profile of Anna Z Mykytyn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
2019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Breugem T, Riesebosch S, Zhang J, Mykytyn A, Krabbendam L, Groen N, et al.
Proc Natl Acad Sci U S A
. 2025 Mar;
122(11):e2410630122.
PMID: 40048293
Transmissibility of respiratory viruses is a complex viral trait that is intricately linked to tropism. Several highly transmissible viruses, including severe acute respiratory syndrome coronavirus 2 and Influenza viruses, specifically...
2.
Brangel P, Tureli S, Muhlemann B, Liechti N, Zysset D, Engler O, et al.
Viruses
. 2025 Jan;
16(12).
PMID: 39772242
Setting up a global SARS-CoV-2 surveillance system requires an understanding of how virus isolation and propagation practices, use of animal or human sera, and different neutralisation assay platforms influence assessment...
3.
Sarink M, Mykytyn A, Jedidi A, Houweling M, Brouwers J, Ruijter G, et al.
Int J Parasitol
. 2024 Nov;
55(1):35-44.
PMID: 39490506
Acanthamoebae, pathogenic free-living amoebae, can cause Granulomatous Amoebic Encephalitis (GAE) and keratitis, and for both types of infection, no adequate treatment options are available. As the metabolism of pathogens is...
4.
Raadsen M, Dahlke C, Fathi A, Hardtke S, Kluver M, Krahling V, et al.
Lancet Infect Dis
. 2024 Oct;
25(2):231-242.
PMID: 39389076
Background: MERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia...
5.
Kaiser F, Hernandez M, Kruger N, Englund E, Du W, Mykytyn A, et al.
Nat Commun
. 2024 Mar;
15(1):2319.
PMID: 38485931
Monoclonal antibodies are an increasingly important tool for prophylaxis and treatment of acute virus infections like SARS-CoV-2 infection. However, their use is often restricted due to the time required for...
6.
Ribo-Molina P, van Nieuwkoop S, Mykytyn A, van Run P, Lamers M, Haagmans B, et al.
mSphere
. 2024 Jan;
9(2):e0074323.
PMID: 38265200
Importance: Human metapneumovirus (HMPV) is one of the leading causative agents of respiratory disease in humans, with no treatment or vaccine available yet. The use of primary epithelial cultures that...
7.
Sadhu S, Dandotiya J, Dalal R, Khatri R, Mykytyn A, Batra A, et al.
Antiviral Res
. 2023 Nov;
220:105743.
PMID: 37949319
The COVID-19 pandemic caused by SARS-CoV-2, lead to mild to severe respiratory illness and resulted in 6.9 million deaths worldwide. Although vaccines are effective in preventing COVID-19, they may not...
8.
Mykytyn A, Fouchier R, Haagmans B
Curr Opin Virol
. 2023 Aug;
62:101349.
PMID: 37647851
SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in December 2019. Vaccines developed were very effective initially, however, the virus has shown remarkable evolution with multiple...
9.
Chatterjee M, Huang L, Mykytyn A, Wang C, Lamers M, Westendorp B, et al.
PLoS Pathog
. 2023 Aug;
19(8):e1011571.
PMID: 37561789
Mucins play an essential role in protecting the respiratory tract against microbial infections while also acting as binding sites for bacterial and viral adhesins. The heavily O-glycosylated gel-forming mucins MUC5AC...
10.
Mykytyn A, Breugem T, Geurts M, Beumer J, Schipper D, van Acker R, et al.
J Virol
. 2023 Aug;
97(8):e0085123.
PMID: 37555660
SARS-CoV-2 can enter cells after its spike protein is cleaved by either type II transmembrane serine proteases (TTSPs), like TMPRSS2, or cathepsins. It is now widely accepted that the Omicron...